Lovastatin

Summary

Lovastatin (CHEMBL503) is an approved small-molecule antineoplastic agent (ATC C10AA02) targeting NR1I2 and HMGCR; indicated across 34 conditions including cardiovascular disorder and coronary artery disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C10AA02
• Targets: 2 (NR1I2, HMGCR)
• Indications: 34 conditions
• Clinical trials: 51
• Chemistry: 404.5 Da · C24H36O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL503
Name	Lovastatin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	53232
ChEBI	CHEBI:40303
ATC	C10AA02
Molecular formula	C24H36O5
Molecular weight	404.5
InChIKey	PCZOHLXUXFIOCF-BXMDZJJMSA-N

SMILES: CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C

IUPAC name: [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] (2S)-2-methylbutanoate

ChEBI definition: A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).

Pharmacological roles (ChEBI): antineoplastic agent, prodrug, anticholesteremic drug.

Other ChEBI roles (chemical / environmental): Aspergillus metabolite.

Also known as: 6.alpha.-methylcompactin, Altoprev, C10AA02, L-154803, Lovastatin, Lovastatin component of advicor, Lovastatina, Lovastatine, Mevacor, Mevinacor, Mevinacor 10, Mevinacor 40

Patent coverage: 24,516 distinct patent families (92,462 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
NR1I2	Pregnane X receptor	Full agonist	6	0.3%	O75469
HMGCR	hydroxymethylglutaryl-CoA reductase	Competitive	7.3	84.4%	P04035

Broader ChEMBL bioactivity targets: 40 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Nuclear receptor ROR-gamma, Survival motor neuron protein, Fructose-bisphosphate aldolase, Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Ferritin light chain, Solute carrier organic anion transporter family member 1B1, Integrin alpha-L, 5-hydroxytryptamine receptor 2B, Protein deacetylase HDAC6, Histone deacetylase 2, Thyrotropin receptor, Thromboxane A2 receptor, Progesterone receptor, Intercellular adhesion molecule (ICAM-1), Integrin alpha-L/beta-2, Sodium-dependent noradrenaline transporter, Adenosine receptor A1.

Bioactivity

ChEMBL activities: 44 potent at pChembl ≥ 5 of 89 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HMGCR	9.22	Ki	0.6	nM	CHEMBL_ACT_2430364
HMGCR	8.7	IC50	2	nM	CHEMBL_ACT_2430365
HMGCR	8.66	IC50	2.2	nM	CHEMBL_ACT_18168813
P51639	8.66	IC50	2.2	nM	CHEMBL_ACT_25041351
P51639	8.66	IC50	2.2	nM	CHEMBL_ACT_29284798
P51639	8.52	IC50	3	nM	CHEMBL_ACT_174222
P51639	8.15	IC50	7	nM	CHEMBL_ACT_725201
P51639	8.1	IC50	8	nM	CHEMBL_ACT_1081602
P51639	8.1	IC50	8	nM	CHEMBL_ACT_513025
P51639	8.1	IC50	8	nM	CHEMBL_ACT_969431
P51639	7.96	IC50	11	nM	CHEMBL_ACT_572903
HMGCR	7.7	IC50	20	nM	CHEMBL_ACT_1103907
HMGCR	7.7	IC50	20	nM	CHEMBL_ACT_7753303
P51639	7.57	IC50	27	nM	CHEMBL_ACT_124891
Q01237	7.57	IC50	27	nM	CHEMBL_ACT_378179
P51639	7.55	IC50	28	nM	CHEMBL_ACT_1301610
HMGCR	7.53	IC50	29.5	nM	CHEMBL_ACT_12718210
HMGCR	7.53	IC50	29.5	nM	CHEMBL_ACT_17700742
HMGCR	7.53	IC50	29.5	nM	CHEMBL_ACT_17773210
P51639	7.5	IC50	32	nM	CHEMBL_ACT_124892
P51639	7.5	IC50	32	nM	CHEMBL_ACT_378180
HMGCR	7.43	IC50	37	nM	CHEMBL_ACT_108166
HMGCR	7.41	IC50	39	nM	CHEMBL_ACT_378181
HMGCR	7.3	IC50	50	nM	CHEMBL_ACT_1081603
HMGCR	7.3	IC50	50	nM	CHEMBL_ACT_969433
P51639	6.4	IC50	400	nM	CHEMBL_ACT_173175
P51639	6.28	IC50	530	nM	CHEMBL_ACT_1044595
P81908	5.96	Ki	1100	nM	CHEMBL_ACT_12481281
ITGB2	5.62	IC50	2400	nM	CHEMBL_ACT_20604678
O42275	5.57	Ki	2700	nM	CHEMBL_ACT_12481277
ITGB2	5.42	IC50	3780	nM	CHEMBL_ACT_511845
P81908	5.3	Ki	5012	nM	CHEMBL_ACT_12481295
LMNA	5.25	Potency	5623	nM	CHEMBL_ACT_3643963
P51450	5.15	Potency	7080	nM	CHEMBL_ACT_4762927
SLC6A3	5.09	Ki	8028	nM	CHEMBL_ACT_7753274
SLC6A2	5.06	IC50	8753	nM	CHEMBL_ACT_7753209
SLC6A2	5.06	Ki	8680	nM	CHEMBL_ACT_7753210
TACR2	5.03	Ki	9408	nM	CHEMBL_ACT_7755466
ABCB1	5	IC50	10000	nM	CHEMBL_ACT_11000938
HIF1A	5	Potency	10000	nM	CHEMBL_ACT_4125688
HIF1A	5	Potency	10000	nM	CHEMBL_ACT_4519897
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_4977773
CYP3A4	5	Potency	10000	nM	CHEMBL_ACT_5046801
SLC6A3	5	IC50	10100	nM	CHEMBL_ACT_7753273

Target pathways

Aggregated over 2 target gene(s): NR1I2, HMGCR.

Top Reactome pathways

7 total, by targets touching each:

Pathway	Targets	Genes
Cholesterol biosynthesis	1	HMGCR
PPARA activates gene expression	1	HMGCR
Activation of gene expression by SREBF (SREBP)	1	HMGCR
Nuclear Receptor transcription pathway	1	NR1I2
SUMOylation of intracellular receptors	1	NR1I2
EGR2 and SOX10-mediated initiation of Schwann cell myelination	1	HMGCR
Lanosterol biosynthesis	1	HMGCR

Dominant GO biological processes

GO term	Targets
steroid metabolic process	2
negative regulation of transcription by RNA polymerase II	1
regulation of DNA-templated transcription	1
xenobiotic metabolic process	1
signal transduction	1
gene expression	1
positive regulation of gene expression	1
cell differentiation	1
intracellular receptor signaling pathway	1
xenobiotic catabolic process	1
xenobiotic transport	1
negative regulation of DNA-templated transcription	1
positive regulation of DNA-templated transcription	1
positive regulation of transcription by RNA polymerase II	1
intestinal epithelial structure maintenance	1

Indications & clinical

Indications

3 approved indications. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319
coronary artery disorder	4	MONDO:0005010	EFO:0001645
atherosclerosis	4	MONDO:0005311	EFO:0003914

25 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
intermittent vascular claudication	3	MONDO:0005295	EFO:0003876
myocardial ischemia	3	MONDO:0024644	EFO:1001375
heart disorder	3	MONDO:0005267	EFO:0003777
peripheral vascular disease	3	MONDO:0005294	EFO:0003875
chronic obstructive pulmonary disease	2	MONDO:0005002	EFO:0000341
HIV infectious disease	2	MONDO:0005109	EFO:0000764
rheumatoid arthritis	2	MONDO:0008383	EFO:0000685
melanoma	2	MONDO:0005105	EFO:0000756
internal carotid artery stenosis	2	MONDO:0005189	EFO:0002615
cerebral atherosclerosis	2	MONDO:0006694	EFO:1000860
learning disability	2	MONDO:0004681	MONDO:0004681
breast neoplasm	2	MONDO:0021100	MONDO:0007254
ovarian cancer	2	MONDO:0008170	MONDO:0008170
arteriovenous malformations of the brain	2	MONDO:0007154	Orphanet:46724
Parkinson disease	2	MONDO:0005180	MONDO:0005180
cerebrotendinous xanthomatosis	2	MONDO:0008948	MONDO:0008948
fragile X syndrome	2	MONDO:0010383	MONDO:0010383
Rett syndrome	2	MONDO:0010726	MONDO:0010726
neurofibromatosis type 1	2	MONDO:0018975	MONDO:0018975
cerebrovascular disorder	2	MONDO:0011057	EFO:0003763
stroke disorder	1	MONDO:0005098	EFO:0000712
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222
metabolic disease	1	MONDO:0005066	EFO:0000589
porokeratosis	1	MONDO:0006602	EFO:1000757
asthma	1	MONDO:0004979	MONDO:0004979

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 51.

Phase distribution

Phase	Trials
PHASE2	22
PHASE3	9
PHASE1	6
Not specified	6
PHASE4	4
PHASE1/PHASE2	2
PHASE2/PHASE3	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00345657	PHASE4	COMPLETED	Efficacy Study of Extended-Release Niacin/Lovastatin Versus Usual Care
NCT01346670	PHASE4	COMPLETED	Lovastatin and Its ß-hydroxy Acid From Four 600 mg LipoCol Forte® Capsules Compared to That of One 20 mg Mevacor® Tablet in Healthy Subjects
NCT01527669	PHASE4	COMPLETED	The Pharmacokinetic Study of Red Yeast Rice Capsule Compared to Lovastatin Tablet in Healthy Subjects
NCT02642653	PHASE4	COMPLETED	Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome
NCT00000463	PHASE3	COMPLETED	Post Coronary Artery Bypass Graft (CABG) Study
NCT00000512	PHASE3	COMPLETED	Familial Atherosclerosis Treatment Study
NCT00062556	PHASE3	COMPLETED	Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication
NCT00071266	PHASE3	COMPLETED	The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
NCT00092846	PHASE3	COMPLETED	A 6-Month Consumer Behavior Study of a Self-Management System (0803-084)(COMPLETED)
NCT00116870	PHASE2/PHASE3	COMPLETED	MARS - Monitored Atherosclerosis Regression Study
NCT00132717	PHASE3	COMPLETED	A 12 Week Study of MK0653A in Patients Who Have Been Hospitalized for a Possible Heart Problem (0653A-808)
NCT00718796	PHASE3	COMPLETED	Naturopathic Treatment for the Prevention of Cardiovascular Disease
NCT03510715	PHASE3	COMPLETED	An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
NCT03510884	PHASE3	COMPLETED	An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia
NCT02964884	PHASE2	ACTIVE_NOT_RECRUITING	Interventions for Reading Disabilities in NF1
NCT06636734	PHASE2	RECRUITING	Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
NCT00000469	PHASE2	COMPLETED	Asymptomatic Carotid Artery Plaque Study (ACAPS)
NCT00000477	PHASE2	COMPLETED	Cholesterol Reduction in Seniors Program (CRISP)
NCT00004346	PHASE2	UNKNOWN	Phase II Study of Cholesterol- and Cholestanol-Free Diet, Lovastatin, and Chenodeoxycholic Acid for Cerebrotendinous Xanthomatosis
NCT00285857	PHASE2	TERMINATED	Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
NCT00302952	PHASE2	TERMINATED	Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis
NCT00462280	PHASE2	COMPLETED	Lovastatin in Treating Patients At High Risk of Melanoma
NCT00580970	PHASE2	COMPLETED	Study of Effectiveness of Lovastatin to Prevent Radiation-Induced Rectal Injury
NCT00583102	PHASE1/PHASE2	TERMINATED	Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML
NCT00585052	PHASE2	TERMINATED	A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer
NCT00689806	PHASE1/PHASE2	WITHDRAWN	Evaluation of Lovastatin in Severe Persistent Asthma
NCT00700921	PHASE2	COMPLETED	Lovastatin as a Potential Modulator of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)
NCT00721305	PHASE2	COMPLETED	Lovastatin: Immunomodulatory Value Evaluation
NCT00902668	PHASE2	TERMINATED	Lovastatin in Reducing Side Effects After Radiation Therapy in Women With Breast Cancer
NCT00963664	PHASE2	WITHDRAWN	Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
NCT01110642	PHASE2	WITHDRAWN	Novel Treatment for Syndromic Ichthyoses
NCT02389868	PHASE2	COMPLETED	Effects of Lovastatin on Human Platelet Proteome
NCT02563860	PHASE2	COMPLETED	Pharmacological Treatment of Rett Syndrome With Statins
NCT02680379	PHASE2	COMPLETED	Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome
NCT03242499	PHASE2	UNKNOWN	Lovastatin as a Neuroprotective Treatment for Early Stage Parkinson’s Disease
NCT03504501	PHASE2	TERMINATED	Synaptic Plasticity and Cognitive Function in RASopathies
NCT03981601	PHASE2	UNKNOWN	Evaluation, the Histomorphometric Study of Nanocrystalline Hydroxyapatite (Nano Bone) Wif Lovastatin in the Preservation of the Tooth Socket
NCT04297033	PHASE2	UNKNOWN	Lovastatin for Treatment of Brain Arteriovenous Malformations
NCT00243880	PHASE1	COMPLETED	Neuroprotection With Statin Therapy for Acute Recovery Trial (Neu-START)
NCT00352599	PHASE1	COMPLETED	Trial to Evaluate the Safety of Lovastatin in Individuals With Neurofibromatosis Type I (NF1)
NCT00584012	PHASE1	TERMINATED	A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer
NCT01250535	PHASE1	COMPLETED	Human Cytochrome P450 4F Enzymes and Drug Interactions
NCT02603770	PHASE1	COMPLETED	Compare Pharmacokinetic(PK) Profiles of XZK vs Lovastatin in Healthy Male Volunteers
NCT04359823	PHASE1	COMPLETED	DSAP Treatment Comparison: 2% Lovastatin/ 2% Cholesterol vs 2% Lovastatin Alone
NCT02998151	EARLY_PHASE1	COMPLETED	Neurophysiological and Acute Pharmacological Studies in FXS Patients
NCT01361217	Not specified	COMPLETED	The Effects of Multiple Dose Fluoxetine and Metabolites on CYP1A2, CYP2C19, CYP2D6 and CYP3A4 Activity
NCT01478828	Not specified	TERMINATED	Pre-Prostatectomy Lovastatin on Prostate Cancer
NCT02518503	Not specified	COMPLETED	High Potency Statins and the Risk of Diabetes
NCT02518516	Not specified	COMPLETED	High Potency Statins and Acute Kidney Injury
NCT03826940	Not specified	COMPLETED	From Molecules to Cognition: Inhibitory Mechanisms in ASD and NF1
NCT06789497	Not specified	COMPLETED	The GABAergic Inhibitory System in Drug Resistant Epilepsy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

PharmGKB dosing guidelines (3) — CPIC / DPWG genotype-guided dosing for this drug (drug × pharmacogene):

Guideline	Source	Gene(s)	Dosing	Recommendation
Annotation of CPIC Guideline for lovastatin and SLCO1B1	CPIC	SLCO1B1	yes	yes
Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatin	CPIC	ABCG2
Annotation of CPIC Guideline for atorvastatin, fluvastatin, lovastatin	CPIC	CYP3A4;CYP3A5;HMGCR

PharmGKB also curates 12 clinical and 17 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

286 molecules share ≥1 primary target. Top 100 by shared-target count:

Molecule	Source	Status	Shared targets
ATORVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	HMGCR, NR1I2
PITAVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	HMGCR, NR1I2
ROSUVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	HMGCR, NR1I2
SIMVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	HMGCR, NR1I2
VORINOSTAT	ChEMBL + PubChem	Phase 4 (approved)	HMGCR, NR1I2
BOSENTAN	ChEMBL + PubChem	Phase 4 (approved)	NR1I2
CRIZOTINIB	ChEMBL + PubChem	Phase 4 (approved)	NR1I2
DACOMITINIB	ChEMBL + PubChem	Phase 4 (approved)	NR1I2
DESOXYCORTICOSTERONE PIVALATE	ChEMBL + PubChem	Phase 4 (approved)	NR1I2
FULVESTRANT	ChEMBL + PubChem	Phase 4 (approved)	NR1I2
GEFITINIB	ChEMBL + PubChem	Phase 4 (approved)	NR1I2
PRAVASTATIN	ChEMBL + PubChem	Phase 4 (approved)	HMGCR
TADALAFIL	ChEMBL + PubChem	Phase 4 (approved)	NR1I2
ABACAVIR	ChEMBL	Phase 4 (approved)	NR1I2
ACENOCOUMAROL	ChEMBL	Phase 4 (approved)	NR1I2
ACETAMINOPHEN	ChEMBL	Phase 4 (approved)	NR1I2
ACITRETIN	ChEMBL	Phase 4 (approved)	NR1I2
ADAPALENE	ChEMBL	Phase 4 (approved)	NR1I2
ALECTINIB	ChEMBL	Phase 4 (approved)	NR1I2
ALPIDEM	ChEMBL	Phase 4 (approved)	NR1I2
AMBRISENTAN	ChEMBL	Phase 4 (approved)	NR1I2
AMLODIPINE	ChEMBL	Phase 4 (approved)	NR1I2
AMSACRINE	ChEMBL	Phase 4 (approved)	NR1I2
ATAZANAVIR	ChEMBL	Phase 4 (approved)	NR1I2
BEDAQUILINE	ChEMBL	Phase 4 (approved)	NR1I2
BENFLUOREX	ChEMBL	Phase 4 (approved)	NR1I2
BENZBROMARONE	ChEMBL	Phase 4 (approved)	NR1I2
BENZTHIAZIDE	ChEMBL	Phase 4 (approved)	NR1I2
BEPRIDIL	ChEMBL	Phase 4 (approved)	NR1I2
BETAMETHASONE DIPROPIONATE	ChEMBL	Phase 4 (approved)	NR1I2
BIFONAZOLE	ChEMBL	Phase 4 (approved)	NR1I2
BITHIONOL	ChEMBL	Phase 4 (approved)	NR1I2
BRIMONIDINE	ChEMBL	Phase 4 (approved)	NR1I2
BROMPERIDOL	ChEMBL	Phase 4 (approved)	NR1I2
BUCLIZINE	ChEMBL	Phase 4 (approved)	NR1I2
BUTENAFINE	ChEMBL	Phase 4 (approved)	NR1I2
BUTOCONAZOLE	ChEMBL	Phase 4 (approved)	NR1I2
CALCIPOTRIENE	ChEMBL	Phase 4 (approved)	NR1I2
CALCITRIOL	ChEMBL	Phase 4 (approved)	NR1I2
CANDESARTAN CILEXETIL	ChEMBL	Phase 4 (approved)	NR1I2
CANNABIDIOL	ChEMBL	Phase 4 (approved)	NR1I2
CAPSAICIN	ChEMBL	Phase 4 (approved)	NR1I2
CARVEDILOL	ChEMBL	Phase 4 (approved)	NR1I2
CEFACLOR	ChEMBL	Phase 4 (approved)	NR1I2
CEFAMANDOLE	ChEMBL	Phase 4 (approved)	NR1I2
CEFEPIME	ChEMBL	Phase 4 (approved)	NR1I2
CEFMENOXIME	ChEMBL	Phase 4 (approved)	NR1I2
CEFOTAXIME	ChEMBL	Phase 4 (approved)	NR1I2
CEFOXITIN	ChEMBL	Phase 4 (approved)	NR1I2
CEFPODOXIME	ChEMBL	Phase 4 (approved)	NR1I2
CEFTAZIDIME	ChEMBL	Phase 4 (approved)	NR1I2
CEFTIZOXIME	ChEMBL	Phase 4 (approved)	NR1I2
CEFTRIAXONE	ChEMBL	Phase 4 (approved)	NR1I2
CEFUROXIME	ChEMBL	Phase 4 (approved)	NR1I2
CEPHALORIDINE	ChEMBL	Phase 4 (approved)	NR1I2
CEPHALOTHIN	ChEMBL	Phase 4 (approved)	NR1I2
CEPHAPIRIN	ChEMBL	Phase 4 (approved)	NR1I2
CEPHRADINE	ChEMBL	Phase 4 (approved)	NR1I2
CERIVASTATIN	ChEMBL	Phase 4 (approved)	HMGCR
CHLORHEXIDINE	ChEMBL	Phase 4 (approved)	NR1I2
CHLOROXINE	ChEMBL	Phase 4 (approved)	NR1I2
CHLORPROTHIXENE	ChEMBL	Phase 4 (approved)	NR1I2
CICLESONIDE	ChEMBL	Phase 4 (approved)	NR1I2
CICLOPIROX	ChEMBL	Phase 4 (approved)	NR1I2
CISAPRIDE	ChEMBL	Phase 4 (approved)	HMGCR
CLEMASTINE	ChEMBL	Phase 4 (approved)	NR1I2
CLOBETASOL PROPIONATE	ChEMBL	Phase 4 (approved)	NR1I2
CLOPIDOGREL	ChEMBL	Phase 4 (approved)	NR1I2
CLOTRIMAZOLE	ChEMBL	Phase 4 (approved)	NR1I2
CYCLANDELATE	ChEMBL	Phase 4 (approved)	NR1I2
DABIGATRAN ETEXILATE	ChEMBL	Phase 4 (approved)	NR1I2
DABRAFENIB	ChEMBL	Phase 4 (approved)	NR1I2
DACLATASVIR	ChEMBL	Phase 4 (approved)	NR1I2
DANAZOL	ChEMBL	Phase 4 (approved)	NR1I2
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	NR1I2
DEMECLOCYCLINE	ChEMBL	Phase 4 (approved)	NR1I2
DESOGESTREL	ChEMBL	Phase 4 (approved)	NR1I2
DESOXIMETASONE	ChEMBL	Phase 4 (approved)	NR1I2
DIETHYLSTILBESTROL	ChEMBL	Phase 4 (approved)	NR1I2
DIHYDROTACHYSTEROL	ChEMBL	Phase 4 (approved)	NR1I2
DIMERCAPROL	ChEMBL	Phase 4 (approved)	NR1I2
DINOPROSTONE	ChEMBL	Phase 4 (approved)	NR1I2
DOMPERIDONE	ChEMBL	Phase 4 (approved)	NR1I2
DRONABINOL	ChEMBL	Phase 4 (approved)	NR1I2
DROXIDOPA	ChEMBL	Phase 4 (approved)	NR1I2
EBASTINE	ChEMBL	Phase 4 (approved)	NR1I2
ECONAZOLE	ChEMBL	Phase 4 (approved)	NR1I2
EFAVIRENZ	ChEMBL	Phase 4 (approved)	NR1I2
ENCORAFENIB	ChEMBL	Phase 4 (approved)	NR1I2
ENZALUTAMIDE	ChEMBL	Phase 4 (approved)	NR1I2
EPALRESTAT	ChEMBL	Phase 4 (approved)	NR1I2
ETHINYL ESTRADIOL	ChEMBL	Phase 4 (approved)	NR1I2
FEDRATINIB	ChEMBL	Phase 4 (approved)	NR1I2
FELODIPINE	ChEMBL	Phase 4 (approved)	NR1I2
FENTANYL	ChEMBL	Phase 4 (approved)	NR1I2
FENTICONAZOLE	ChEMBL	Phase 4 (approved)	NR1I2
FLUOROMETHOLONE	ChEMBL	Phase 4 (approved)	NR1I2
FLUSPIRILENE	ChEMBL	Phase 4 (approved)	NR1I2
FLUTICASONE PROPIONATE	ChEMBL	Phase 4 (approved)	NR1I2
FLUTRIMAZOLE	ChEMBL	Phase 4 (approved)	NR1I2